Recent news on Enoxaparin

FDA Approves Enoxaparin for STEMI  -  25 May 2007
Medscape (subscription)May 24, 2007 — The US Food and Drug Administration (FDA) has approved enoxaparin (Lovenox) for treatment of acute ST-segment elevation myocardial infarction

FDA Approves Lovenox® (Enoxaparin Sodium Injection) For The Most ...  -  May 20, 2007
Medical News Today (press release),The FDA approval is based on the results of the landmark ExTRACT-TIMI 25 trial (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial InfarCtion

FDA approves enoxaparin for STEMI  -  May 18, 2007
TheHeart.Org,The approval was made on the basis of the EXTRACT-TIMI 25 trial, in which enoxaparin reduced the rate of recurrent MI or death in patients receiving either

FDA Approves Lovenox(R) (Enoxaparin Sodium Injection) for the Most ...  -  May 17, 2007
Juraforum.de,The FDA approval is based on the results of the landmarkExTRACT-TIMI 25 trial (Enoxaparin and Thrombolysis Reperfusion forAcute Myocardial InfarCtion

APS: FDA Approves Lovenox(R) (Enoxaparin Sodium Injection) for ...  -  May 17, 2007
ANP Pers Support,...the enoxaparin group and 1.4 in the UFH group (p<0.001). The 30 day rate of the composite. compared to the unfractionated heparin group (10.1 vs.

Sanofi-Aventis gets OK in USA for expanded use of Lovenox  -  May 21, 2007
Pharma Times (subscription),The US Food and Drug Administration has approved a supplemental New Drug for Lovenox (enoxaparin) for the treatment of patients with acute ST-segment

Lovenox For The Most Severe Type Of Heart Attack Treatment ...  -  May 18, 2007
eMaxHealth.com,Food and Drug Administration has approved a supplemental New Drug Application for the anticoagulant Lovenox (enoxaparin sodium injection) for the treatment

Glycoprotein IIb/IIIa Inhibitors Associated With Major Bleeding in ...  -  May 14, 2007
DG NewsDr. Cohen and colleagues performed a subanalysis of the Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention Patients (STEEPLE) trial,

Momenta Pharmaceuticals Reports Financial Results for the First ...  -  May 8, 2007
Primenewswire (press release),..."We have been active in furthering our efforts to achieve marketing approval of M-Enoxaparin, driving the progress in the development plan of M356,

Sanofi-aventis Is Trading Higher In Pre-market Session Following ...  -  May 18, 2007
Trading Markets,...the anticoagulant Lovenox, enoxaparin sodium injection, for the treatment of patients with acute ST-segment elevation myocardial infarction or STEMI.

Momenta Pharmaceuticals to Present At the Acumen BioFion Rodman ...  -  May 14, 2007
Primenewswire (press release),The Company's most advanced product candidate, M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox(r). Momenta's first novel drug

Where is Momenta's Momentum?  -  May 9, 2007
Motley FoolMomenta isn't the only drugmaker expecting approval of its generic enoxaparin product. Competitor Watson Pharmaceuticals (NYSE: WPI) has been guiding

Sanofi raises profit forecast despite Ambien generic threat  -  May 3, 2007
Pharma Times (subscription),Sales of the antithrombotic Lovenox (enoxaparin) rose 8.2% in the quarter to 634 million euros while the stellar performance came from the Stilnox/Ambien

Pharma firms eye in-licensing opportunities  -  Apr 26, 2007
Business Standard,Another pharma major Lupin in-licensed a cardiovascular critical care product, Enoxaparin Sodium Injection, in pre-filled syringes under the brand name

Enoxaparin more beneficial in strokes than other blood thinners: Study  -  Apr 21, 2007
Earthtimes.orgDr Sherman said that around half of the patients were administered a daily dose of enoxaparin injections while the other half were given unfractionated

Enoxaparin Outdoes Heparin for Post-Stroke Venous Thromboembolism  -  Apr 20, 2007
MedPage Today,In a head-to-head study of 1762 stroke patients unable to walk unassisted, enoxaparin was 43% more effective at preventing venous thromboembolism than

PREVAIL: Enoxaparin bests heparin for VTE prophylaxis poststroke  -  Apr 20, 2007
TheHeart.Org,These results, from the Prevention of VTE After Acute Ischemic Stroke with LMWH Enoxaparin (PREVAIL) study, presented previously at the American Society of

Lovenox Better Than Unfractionated Heparin For Acute Ischemic ...  -  Apr 23, 2007
eMaxHealth.com,Sanofi-aventis announced the publication of the PREVAIL (Prevention of VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial.

The Lancet Publishes PREVAIL Study Results Showing Lovenox(R ...  -  Apr 21, 2007
Medical News Today (press release),Sanofi-aventis announced the publication of the PREVAIL (Prevention of VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial in the April 21st issue

The Lancet Publishes PREVAIL Study Results Showing Lovenox(R ...  -  Apr 20, 2007
PR Newswire (press release),The results of the trial showed that once daily administration of Clexane(R) / Lovenox(R) (enoxaparin sodium injection) 40 mg was more effective than

Newer Form of Heparin Better at Preventing Clots After Stroke  -  Apr 20, 2007
CBC News,The incidence of clots in the lungs and legs of stroke patients who got the engineered form, called enoxaparin, was 43 percent lower than in those who got

Stopping Fatal Blood Clots After Acute Ischaemic Stroke  -  Apr 20, 2007
Medical News Today (press release),Enoxaparin is more effective than unfractionated heparin at stopping fatal blood clots in the veins of the legs and lungs following an acute ischaemic

A Better Blood Thinner  -  Apr 20, 2007
WFIE-TV,According to investigators who compared the two drugs -- enoxaparin and unfractionated heparin -- enoxaparin was 43-percent more effective at preventing

The Lancet Publishes PREVAIL Study Results  -  Apr 20, 2007
Newsdesk,Enoxaparin is an anticoagulant of the low molecular weight heparin (LMWH) class. Its clinical. applications are linked to its antithrombotic properties.

Sanofi blood thinner better than older drug: study  -  Apr 19, 2007
Scientific AmericanResearchers compared Sanofi's Lovenox, a once-daily injection known generically as enoxaparin, with unfractionated heparin, a cheaper, twice-daily treatment

Treatment With Bivalirudin Alone Gets Equivalent Results as ...  -  Mar 28, 2007
DG NewsAfter 1-year of follow-up, the 3 study arms were as follows: 4516 patients received heparin or enoxaparin and GP IIb/IIIa inhibitors; 4502 patients received

Momenta Pharmaceuticals to Present At the Deutsche Bank - 32nd ...  -  Apr 24, 2007
PharmaLive.com (press release),The Company's most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox(r).

Momenta Pharmaceuticals to Present at the Morgan Stanley Global ...  -  Apr 24, 2007
Primenewswire (press release),The Company's most advanced product candidate, M-Enoxaparin, is designed to be a technology-enabled generic version of Lovenox(r).

Angiomax on its own shows success  -  Mar 28, 2007
United Press International...bivalirudin is an acceptable substitute for either unfractionated heparin or enoxaparin," said Gregg Stone, director of Cardiovascular Research and

Portola Pharmaceuticals Announces Positive Phase II Results for ...  -  Apr 4, 2007
PipelineReview.com (press release),EXPERT (Evaluation of the Factor Xa Inhibitor, PRT054021, against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic Events after

Reuters Health News Summary  -  Apr 20, 2007
San Diego Union Tribune,Researchers compared Sanofi's Lovenox, a once-daily injection known generically as enoxaparin, with unfractionated heparin, a cheaper, twice-daily

Sanofi-aventis (SNY) Says Published Report has PREVAIL Study ...  -  Apr 20, 2007
StreetInsider.com (subscription),Sanofi-aventis (NYSE: SNY) announced the publication of the PREVAIL (Prevention of VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial in the April

Momenta Pharmaceuticals Announces Date of Earnings Release and ...  -  Apr 18, 2007
Primenewswire (press release),The Company's most advanced product candidate, M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox(r). Momenta's first novel drug

Physicians Aggressively Treat Evolving MI Without Waiting for Test ...  -  Apr 17, 2007
Medscape (subscription)The finding comes from the international SYNERGY trial (Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa

Doctors Aggressively Treat Early Heart Attacks, Research Shows  -  Apr 13, 2007
Medical News Today (press release),The research was an analysis of a larger trial, the Superior Yield of the New strategy of Enoxaparin, Revascularization, and GlYcoprotein IIb/IIIa

Pipeline Insight: Antithrombotics - Reaching the untreated ...  -  Apr 10, 2007
Pharmaceutical Business ReviewThe highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents will be genericized within our

Doctors Pre-empt Tests in Treating Early Heart Attacks  -  Apr 9, 2007
HeartZine,Results of the research, which was part of a larger trial, the “Superior Yield of the New strategy of Enoxaparin, Revascularization, and GlYcoprotein

'Angiox' Licensed For Use In PCI, As Effective As More Complicated ...  -  Apr 2, 2007
Medical News Today (press release),ACUITY (Acute Catheterisation and Urgent Intervention Triage strategY) was designed to show that, when compared with heparins (unfractionated or enoxaparin)

Studies Highlight Advances In Diagnosis, Medical Therapy And ...  -  Apr 1, 2007
Medical News Today (press release),...heparin (conventional, unfractionated heparin or a low-molecular-weight alternative, enoxaparin) plus GPI; bivalirudin plus GPI; or bivalirudin alone.

New data show enoxaparin reduces risk of repeat heart attacks and ...  -  Feb 16, 2007
Irish Medical News,These advantages of enoxaparin were observed without an increase in the risk of major bleeding between the enoxaparin and UFH groups (1.4 per cent and 1.6

FDA Grants Priority Review To Lovenox® (Enoxaparin Sodium ...  -  Feb 12, 2007
Medical News Today (press release),The FDA filing is based on the results of the landmark ExTRACT-TIMI 25 trial (Enoxaparin and Thrombosis Reperfusion for Acute Myocardial InfarCtion

FDA Grants Priority Review to Lovenox(R) (Enoxaparin Sodium ...  -  Feb 7, 2007
Therapeutics Daily (subscription) (press release),...(enoxaparin sodium injection) for the treatment of patients with acute ST-segment elevation myocardial infarction (STEMI), a type of acute heart attack.

Anticoagulant agent superior in international PREVAIL study  -  Feb 11, 2007
Antara (press release),They were randomly assigned to be treated with either enoxaparin or the older class of agent, unfractionated heparin, for 10 days and were followed for 90

Low-Molecular-Weight Heparin Superior to Unfractionated Heparin in ...  -  Feb 12, 2007
DG News..."This trial suggests that enoxaparin could become the preferred treatment to prevent deep vein clots in stroke patients," said David Sherman, MD,

Momenta Pharmaceuticals Reports Financial Results for the Fourth ...  -  Feb 13, 2007
Primenewswire (press release),..."In particular, we have the opportunity to realize two important milestones as we progress towards the launch of M-Enoxaparin in the US, including the

Anticoagulant Agent Superior in International PREVAIL Study  -  Feb 9, 2007
PR Newswire UK (press release),SAN FRANCISCO, February 9 /PRNewswire/ -- A 1700-patient study comparing anticoagulation therapies found that enoxaparin, one of a class of compounds called

Safety of Surgery during Bridging Anticoagulation Therapy with Low ...  -  Feb 5, 2007
Annals of Internal MedicineOne member of this class is enoxaparin, a medication that must be given by injection, either once or twice daily. Enoxaparin treatment also must be stopped

Amphastar and Teva Prevail Over Aventis in Generic Lovenox Trial  -  Feb 13, 2007
Seeking Alpha,The patents cover Lovenox (enoxaparin), a low-molecular weight heparin composition exhibiting anticoagulant properties and indicated for the prevention and

Spur of the Momenta: Fool by Numbers  -  Feb 15, 2007
Motley FoolFor 2007, management plans to advance the commercial readiness of the M-Enoxaparin program, complete the phase 1 clinical studies for M118 intravenous

Brief Communication: Preoperative Anticoagulant Activity after ...  -  Feb 5, 2007
Annals of Internal MedicineIntervention: Enoxaparin, 1 mg/kg of body weight, twice daily. The last dose was administered the evening before surgery. Measurements: Blood anti–factor Xa

Is Momenta's Stock Plunge Justified?  -  Feb 12, 2007
Seeking Alpha,The most advanced product candidate, M-Enoxaparin is designed to be a technology-enabled generic version of Lovenox, a low molecular weight heparin,

Sanofi-Aventis loses US patent lawsuit on Lovenox  -  Feb 9, 2007
Pharma Times (subscription),Though no doubt a blow, industry analysts are waiting to see what action the FDA takes before factoring in the possibility of generic enoxaparin hitting the

Momenta Pharmaceuticals 4Q Loss Widens  -  Feb 13, 2007
Forbes,...growth to increased reimbursable expenditures associated with preparing for the potential commercial launch of M-Enoxaparin in the United States.

ANTICOAGULANT AGENT SUPERIOR IN INTERNATIONAL PREVAIL STUDY  -  Feb 12, 2007
Therapeutics Daily (subscription) (press release),A 1700-patient study comparing anticoagulation therapies found that enoxaparin, one of a class of compounds called low-molecular-weight heparins,

French reimbursement agency backs Sanofi's Acomplia  -  Feb 7, 2007
Pharma Times (subscription),...that it has been granted a priority review in the USA for a new indication of its low molecular weight heparin anticoagulant Lovenox (enoxaparin).

Momenta Pharmaceuticals to Present At BIO CEO & Investor ...  -  Feb 6, 2007
PharmaLive.com (press release),The Company's most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox(r). Momenta's first novel drug candidate is

Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in ...  -  Feb 13, 2007
Journal of American Medical Association (subscription),A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in

Pharma Sector: Few Newsmakers Of The Week - Opexa, J&J, Glaxo ...  -  Feb 11, 2007
Trading Markets,Friday, French drug maker Sanofi-Aventis, lost a patent suit over its best-selling blood thinner Lovenox (enoxaparin sodium), filed against generic drug

Sanofi profits hit by generic Plavix and 2007 looks tougher  -  Feb 13, 2007
Pharma Times (subscription),However it was not all bad news on the sales front as turnover from the blood clot drug Lovenox (enoxaparin) improved 12% to 614 million euros,

Management of Venous Thromboembolism: A Clinical Practice ...  -  Feb 5, 2007
Annals of Internal MedicineLow molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the

Sanofi Patent Found Unenforceable Due to Inequitable Conduct  -  Feb 12, 2007
Patent Baristas,Although the patent covering the Lovenox main ingredient (enoxaparin sodium) does not expire until February 14, 2012, a ruling by the US District Court for

Momenta Shares Dip After Patent Decision  -  Feb 9, 2007
Forbes,Chao said the decision amounts to a positive catalyst for Momenta, as it removes the first legal obstacle for the generic launch of M-Enoxaparin.

(PRN) - On Assignment Executives to Present at 2007 UBS Global ...  -  Feb 7, 2007
Bolsamania.com,...(PRN) - FDA Grants Priority Review to Lovenox(R) (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for Acute Heart Attack ... [+]

GSK gets non-approvable FDA letter for Arixtra indications  -  Feb 5, 2007
Pharma Times (subscription),...in at just £13 million for the third quarter of 2006 and may help the drug make some inroads on the market leader Sanofi-Aventis' Lovenox (enoxaparin).

Pipeline match for possible Bristol-Myers Squibb and Sanofi ...  -  Jan 31, 2007
In-PharmaTechnologist.com,Since the 1980s, the company has also marketed the world's best selling low molecular weight heparin, Lovenox (enoxaparin).

Sanofi-aventis 2006: In a Difficult Environment, Another Year of ...  -  Feb 12, 2007
Yahoo! News (press release)The results demonstrated a significant 43% reduction in venous thromboembolism (VTE) events with enoxaparin versus unfractionated heparin (UFH) in

Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin ...  -  18 Jan 2007
Journal of American Medical Association (subscription),Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism. Chest. 2005;128:2203-2210. FREE FULL TEXT. 4. Chong BH, Brighton TA,

Celsus to Commence Phase I Clinical Studies of Intimatan  -  18 Jan 2007
PharmaLive.com (press release),Clexane® low molecular weight heparin market, Celsus is finalizing a FDA drug master file for the active pharmaceutical ingredient, enoxaparin sodium.

Momenta promotes Bishop  -  Dec 22, 2006
Boston Globe,Momenta is working on a product candidate called M-Enoxaparin, a "technology-enabled" generic version of Lovenox, a blood thinner that prevents blood clots

Momenta Pharmaceuticals Announces Executive Promotion  -  Dec 21, 2006
Drug Newswire (press release),..."In particular, he has been instrumental in advancing the analytic and process development work for M-Enoxaparin. This promotion is recognition of his hard

Momenta Pharma (MNTA) March option implied volatility at 138 into ...  -  Dec 27, 2006
StreetInsider.com (subscription),Momenta Pharma (Nasdaq: MNTA) : MNTA is expected to provide an update on M-Enoxaparin ANDA, a generic form of SNY's Lovenox, ($1.5 billion in sales in 2005)

Fondaparinux significantly reduces risk of death for myocardial ...  -  Dec 19, 2006
Xagena.it,Trials of medications such as unfractionated heparin ( UFH ), direct thrombin inhibitors, and Enoxaparin ( Clexane / Lovenox ) have thus far failed to

Factors Associated with Prolonged Wound Drainage After Primary ...  -  Jan 17, 2007
Journal of Bone and Joint Surgery (subscription)...begun on the day of surgery; low-molecular-weight heparin (Lovenox [enoxaparin]) started between twelve and twenty-four hours postoperatively;

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional